(Q39926951)

English

Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8(+) T cell responses

scientific article published on 18 November 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8(+) T cell responses (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

vector-borne disease

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Renata Stripecke

12

object named as

Renata Stripecke

0 references

object named as

Adan C Jirmo

1

0 references

Heiner Wedemeyer

11

object named as

Heiner Wedemeyer

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

author name string

Richard C Koya

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Bala Sai Sundarasetty

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Mudita Pincha

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Guann-Yi Yu

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Michael Lai

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Rakesh Bakshi

7

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Verena Schlaphoff

8

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Jan Grabowski

9

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Georg Behrens

10

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Renata Stripecke

12

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

language of work or name

0 references

publication date

18 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

922-933

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Treating viral hepatitis C: efficacy, side effects, and complications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Development of hepatitis C virus vaccines: challenges and progress.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Flying under the radar: the immunobiology of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Immunology of hepatitis B virus and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Hepatitis C virus-specific T cell responses against conserved regions in recovered patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Proliferating dendritic cell progenitors in human blood

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Clinical trials with tumor antigen genetically modified dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

The use of lentiviral vectors in gene therapy of leukemia: combinatorial gene delivery of immunomodulators into leukemia cells by state-of-the-art vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

CD34 splice variant: an attractive marker for selection of gene-modified cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Lentiviral vector-mediated genetic programming of mouse and human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Priming and stimulation of hepatitis C virus-specific CD4+ and CD8+ T cells against HCV antigens NS4, NS5a or NS5b from HCV-naive individuals: implications for prophylactic vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Major histocompatibility complex class-I presentation impaired in transgenic mice expressing hepatitis C virus structural proteins during dendritic cell maturation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

Replication of the hepatitis C virus in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

A third-generation lentivirus vector with a conditional packaging system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.150

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.10.150

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39926951&oldid=1878708874"